No Data
No Data
Affimed Says Abstract On Phase 2 LuminICE-203 Study Of ICE Acimtamig In Combination With AB-101 Accepted For Oral Presentation At ASCO 2025
Affimed Receives Nasdaq Notice Over Low Share Price, Has Until October to Regain Compliance
Leerink Partners Maintains Affimed NV(AFMD.US) With Buy Rating, Cuts Target Price to $5
H.C. Wainwright Maintains Affimed NV(AFMD.US) With Buy Rating, Maintains Target Price $7
Truist Financial Maintains Affimed NV(AFMD.US) With Buy Rating
H.C. Wainwright Maintains Affimed NV(AFMD.US) With Buy Rating, Cuts Target Price to $7
Rivera : Caming bro
Trytosaveabit OP Rivera : A bit of decent volume could send it upward nicely my friend
Rivera Trytosaveabit OP : Cheers happy holidays
Trytosaveabit OP Rivera : Thank you! A safe and wonderful Christmas to you and yours buddy🩷